MGTX

In November 2025, MeiraGTx announced a strategic collaboration with Eli Lilly and Company in ophthalmology and reported its third-quarter 2025 financial results. In December 2024, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to AAV2-hAQP1. In March 2026, the company announced robust financial results for the fourth quarter and full-year 2025, and the FDA granted Breakthrough Therapy designation to AAV2-hAQP1, leading to a share price increase. In April 2026, MeiraGTx announced the pricing of a $100 million offering of ordinary shares, acquired botaretigene sparoparvovec (bota-vec), presented positive three-year data from the Phase 1 AQUAx clinical study of AAV-hAQP1, and saw Perceptive Advisors and affiliates increase their ownership to 12.6%. Also in April 2026, MeiraGTx detailed a $200 million Hologen CNS gene therapy pact, and analysts downgraded their revenue forecasts for 2026.